Thank you for your question. I think I will answer in English because there are a lot of figures and I want to make sure I get the figures right.
As you mentioned, we have had a backlog in the natural health products area, and we have been working diligently on that.
Maybe I'll start by outlining that we have currently issued over 25,000 natural health product licences, which means there are now over 33,000 products on the market. This is more than the number for over-the-counter drugs.
On how we are addressing the backlog, there has been something of a change in how we're dealing with it, partly because of consultations with stakeholders. We have a new set of regulations that are altering how we deal with this. So we're dealing with the backlog in a different way now, but it's a way that I think stakeholders, including NAPRA, the pharmaceutical association, have found to be quite useful.
Under this regime we have mechanisms that we call the UPLAR--“unprocessed product licence application regulations”. They came into force on August 4. These regulations give us the mechanism to temporarily authorize the sale of certain unlicensed NHPs. So once we've been able to assure ourselves that these natural health products meet key safety criteria--and we can at the same time, if we need to, put conditions on their sale--we can allow them into the market. This gives us the ability to move them forward.
We have currently completed 87% of what would have been considered the backlog under the previous regime. We are on target to continue to move these forward, but we now have a slightly different mechanism of counting because we've changed our mechanism. We think the new regulations give us the ability to move things through and deal more expeditiously with natural health products.